Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7183478 | 0.91 | CYP3A4 (0.47) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL7094675 | 0.87 | CYP3A4 (0.42) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL7179478 | 0.86 | CYP3A4 (0.42) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL1056821 | 0.82 | CYP3A4 (0.50) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL1389204 | 0.81 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL27900691 | 0.81 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL7391613 | 0.81 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL7176885 | 0.81 | CYP3A4 (0.45) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL7091733 | 0.81 | CYP3A4 (0.45) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL7527628 | 0.80 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6667404-B2 | Carbamylation of 1-amino group of 1,4-amino-3-hydroxybutane derivative with an organocarbonate containing thiazolyl, oxazolyl, isoxazolyl or isothiazolyl substituent | ABBOTT LABORATORIES | 2003-12-23 | — | — | US | disclosed |
| EP-1302468-A1 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6531610-B1 | Intermediate acylating carbonate | ABBOTT LABORATORIES | 2003-03-11 | — | — | US | disclosed |
| EP-1090914-A2 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6150530-A | AMIDATION OF AMINE WITH ACID | ABBOTT LABORATORIES (US) | 2000-11-21 | — | — | US | disclosed |
| US-6017928-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2000-01-25 | — | — | US | disclosed |
| US-5990135-A | FOR TREATING A RETROVIRAL INFECTION SUCH AS HIV INFECTION; FOR EXAMPLE 5S-N-((2-PYRIDINYL)METHOXYCARBONYL)VALINYLAMINO-2-((N-3 -PYRIDINYL)METHOXYCARBONYL)AMINO-4S-HYDROXY-1,6-DIPHENYL-2-AZAHEXANE AND OTHER COMPOUNDS OF GIVEN FORMULA | ABBOTT LABORATORIES (US) | 1999-11-23 | — | — | US | disclosed |
| US-5892052-A | Process for making retroviral protease inhibiting compounds | ABBOTT LABORTORIES (US) | 1999-04-06 | — | — | US | disclosed |
| US-5886036-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1999-03-23 | — | — | US | disclosed |
| US-5846987-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1998-12-08 | — | — | US | disclosed |
| US-5591860-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1997-01-07 | — | — | US | disclosed |
| US-5583232-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-10 | — | — | US | disclosed |
| US-5583233-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-10 | — | — | US | disclosed |
| US-5565418-A | PREPARING CARBAMATE INTERMEDIATES BY REACTING SUBSTITUTED HYDROXYDIAMINE COMPOUND WITH ONE AMINE PROTECTED WITH ACTIVATED ACYLATING AGENT, DEPROTECTING | ABBOTT LABORATORIES (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0674513-B1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5552558-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1996-09-03 | — | — | US | disclosed |
| US-5541206-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTION | ABBOTT LABORATORIES (US) | 1996-07-30 | — | — | US | disclosed |
| US-5539122-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1996-07-23 | — | — | US | disclosed |
| US-5461067-A | For HIV infections | ABBOTT LABORATORIES (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1994019332-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-09-01 | — | — | WO | disclosed |